Clinical studies on TMS-19-Q • o tablet in respiratory tract infection

Kohei Hara, Kinichi Izumikawa, Yoji Suzuyama, Yoshiteru Shigeno, Munetaka Komori, Hiroshi Tomita, Masao Sai, Akira Ikebe, Hiromaru Iwasaki, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Seiichi Aonuma, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai, Izumi HayashiTatsuya Abe, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Yasuko Yuasa, Isao Nitta, Kyoko Watanabe, Fusanosuke Yamasaku, Yasutoshi Suzuki, Masataka Katsu, Shinji Okui, Otohiko Kunii, Takashi Komatsu, Hajime Nishiya, Kohya Shiba, Atsushi Saito, Tadashi Miyahara, Keimei Mashimo, Sumio Yamaoka, Keiichi Nakagawa, Masaru Koyama, Teppei Kumada, Hiroyuki Kobayashi, Hiroaki Takeda, Tomoko Nihei, Mitsuo Obana, Yoshio Kobayashi, Ippei Fujimori, Akira Ito, Masanori Matsumura, Kunihiko Shindo, Kokichi Fukushima, Shigeki Odagiri, Makio Kurihara, Hideyuki Hasegawa, Fumio Matsumoto, Masahito Kato, Joichi Kato, Kazuo Yoshitomo, Motoko Yamamoto, Saburo Kitaura, Hidekazu Hanaki, Yoshiyuki Yamamoto, Toshihiko Takeuchi, Fumio Miki, Kenji Takamatsu, Masakazu Kohno, Yuruko Okamoto, Keigo Maehara, Kanshi Mase, Yube Iida, Muneto Yoshioka, Kojiro Yasunaga, Yoshihiro Ueda, Hiroshi Ohkubo, Rinzo Soejima, Yoshito Niki, Masayoshi Kawanishi, Chikara Nakahama, Masatoshi Watanabe, Jiro Hino, Masakazu Tamura, Toshihiro Goto, Yoshihiro Takishita, Eiro Tsubura, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Keizo Matsumoto, Yoshio Uzuka, Naoto Rikitomi, Yasutsugu Fukuda, Katsumasa Tokunaga, Masayuki Ando, Haruhiko Tokuomi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.

Original languageEnglish
Pages (from-to)553-574
Number of pages22
JournalThe Japanese Journal of Antibiotics
Volume38
Issue number3
DOIs
Publication statusPublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical studies on TMS-19-Q • o tablet in respiratory tract infection'. Together they form a unique fingerprint.

Cite this